www.astralcodexten.com/p/link-troof-on-nootropics?utm_source=chatgpt.com

The problem here is not that every trial found strong benefits; many did not. The problem is the claim's level of certainty. Saying "several double-blind studies have now shown this doesn’t work" overstates what the controlled literature supports.

A 2022 systematic review of microdosing research concluded that claims that microdosing effects are largely due to expectancy are "premature and possibly wrong." A later 2024 rapid review focused specifically on placebo-controlled low-dose LSD and psilocybin studies reached a similar bottom line: controlled studies have produced mixed evidence, with both positive findings and null findings, and "it is not yet possible to determine whether microdosing is a placebo."

Even one of the key 2022 double-blind psilocybin papers did not show a blanket absence of any effect. That study reported that low doses of psilocybin mushrooms produced noticeable subjective effects and altered EEG rhythms, while failing to show evidence for enhanced well-being, creativity, or cognitive function. In other words, the study found some measurable effects but not clear support for the popular enhancement claims.

So the literature does not justify the simple statement that double-blind studies have shown psilocybin microdosing "doesn’t work." A more accurate summary would be that controlled evidence is limited and mixed, and has not confirmed the broad benefits claimed by enthusiasts.